The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IPA | +329.32% | -77.31% | -25.67% | -59% |
| S&P | +17.53% | +93.66% | +14.13% | +200% |
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
No news articles found for MindWalk.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.30M | -40.1% |
| Gross Profit | $1.11M | -13.0% |
| Gross Margin | 48.31% | 15.1% |
| Market Cap | $76.62M | 289.4% |
| Market Cap / Employee | $0.75M | 0.0% |
| Employees | 102 | 1.0% |
| Net Income | -$2.97M | -1.9% |
| EBITDA | -$2.34M | 5.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.54M | 25.0% |
| Accounts Receivable | $1.70M | -26.6% |
| Inventory | 0.4 | -72.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.39M | -72.2% |
| Short Term Debt | $0.30M | -90.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.43% | -19.2% |
| Return On Invested Capital | -43.44% | -10.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.27M | -114.7% |
| Operating Free Cash Flow | -$3.07M | -130.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.55 | 0.60 | 1.16 | 4.48 | 394.51% |
| Price to Sales | 0.76 | 0.88 | 1.15 | 4.78 | 295.94% |
| Price to Tangible Book Value | 11.37 | 11.22 | 1.80 | 7.39 | -60.71% |
| Enterprise Value to EBITDA | -21.70 | -11.48 | -56.23 | -32.36 | 164.07% |
| Return on Equity | -66.5% | -121.7% | -102.7% | -110.9% | 76.60% |
| Total Debt | $11.78M | $8.93M | $9.70M | $2.69M | -76.89% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
